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Fv	 antibody	 fragments	 have	 been	 used	 as	 co-crystallization	 partners	 in	
structural	 biology,	 particularly	 in	 membrane	 protein	 crystallography.	








and	 assembly	 of	 the	 two	 variable	 domains.	 The	 iRAT	 segment	 can	 be	
removed	by	a	site-specific	protease	during	the	purification	process	to	yield	
tag-free	 Fv	 fragments	 suitable	 for	 crystallization	 trials.	 In	 vitro	 refolding	
step	is	not	required	to	obtain	correctly	 folded	Fv	fragments.	As	a	proof	of	
concept,	 we	 tested	 the	 iRAT-based	 production	 of	 multiple	 Fv	 fragments,	
including	a	crystallization	chaperone	for	a	mammalian	membrane	protein	
as	 well	 as	 FDA-approved	 therapeutic	 antibodies.	 The	 resulting	 Fv	






A	 50-75-word	 statement,	 written	 for	 a	 broader	 audience,	 outlining	 the	
importance	and/or	impact	of	the	work	presented	in	the	manuscript:	




Structural	studies	of	key	proteins	that	are	involved	in	biologically	and	medically	relevant	molecular	processes	are	frequently	abandoned	because	of	difficulties	in	preparing	 diffraction-quality	 crystals.	 In	most	 cases,	 their	molecular	 flexibility,	conformational	 heterogeneity	 or	 polydispersal	 characteristics	 in	 solution	hinders	protein	crystallization.	Chaperone-assisted	crystallography	is	a	powerful	strategy	 to	 address	 this	 problem	 and	 can	 be	 applied	 to	 a	 broad	 range	 of	membrane	 proteins	 and	 otherwise	 ‘uncrystallizable’	 soluble	 proteins,	 such	 as	heavily	glycosylated	and	multi-domain	proteins1,2.	The	chaperone	molecules	aid	in	 crystallization	 by	 increasing	 the	 hydrophilic	 surface	 area	 available	 for	 rigid	crystal	 lattice	 formation.	 The	 bound	 chaperone	molecules	 reduce	 the	 inherent	protein	 flexibility	 and	 conformational	 heterogeneity,	 thereby	 increasing	 the	chance	of	successful	crystallization	of	difficult	target	proteins.	
Different	protein	scaffolds	have	been	used	as	crystallization	chaperones,	ranging	from	animal-derived	antibody	fragments3,4	to	synthetic	binders	such	as	DARPins5	and	Monobodies6.	DNA	and	RNA	aptamers	have	also	been	applied	as	co-crystallization	 partners7,8.	 Among	 the	 reported	 chaperones,	 Fv	 antibody	fragment	is	a	promising	scaffold	that	has	been	used	to	crystallize	of	a	variety	of	membrane	 proteins	 including	 bacterial	 cytochrome	 c	 oxidase9,10,	 yeast	cytochrome	 bc1	 complex11,	 archaeal	 KvAP	 voltage-gated	 potassium	 channel12,	human	 adiponectin	 receptors13	 and	 the	 mammalian	 fructose	 transporter	GLUT514.	 In	 addition,	 the	 compactness	 of	 Fv	 fragments	 affords	 additional	advantages	in	structural	studies	examining	the	antigen-antibody	interface,	such	as	the	characterization	of	therapeutic	antibody	blocking	mechanisms15,16.	
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Preparation	of	milligram	quantities	of	purified	Fv	 fragments	 is	 the	most	critical	prerequisite	when	Fv	 fragments	are	used	as	co-crystallization	partners.	Several	 studies	 evaluating	 the	 quantity	 and	 quality	 of	 Fv	 fragments	 produced	from	 different	 expression	 systems	 have	 been	 performed.	 Bicistronic	 VL-VH	overexpression	 in	 the	Escherichia	coli	periplasm	results	 in	 relatively	 low	yields	(0.5-1	mg	per	liter	of	culture)17.	Recovery	of	functional	Fv	fragments	from	E.	coli	cytoplasmic	inclusion	bodies	requires	a	laborious	and	time-consuming	refolding	process	 during	 purification18.	 In	 contrast,	 Gram-positive	 bacteria	 lack	 an	 outer	membrane	and	have	a	powerful	secretion	apparatus	 that	allows	disulfide	bond	formation	 and	 the	 proper	 folding	 of	 antibody	 fragments	 in	 an	 oxidizing	environment.	 Bicistronic	 VL-VH	 secretory	 expression	 has	 been	 tested	 in	
Streptomyces	 lividans	 to	 purify	 a	 certain	 Fv	 fragment19,	 but	 it	 is	 not	 known	whether	 this	 method	 can	 be	 practically	 applied	 to	 a	 wide	 range	 of	 antibody	clones.	Production	of	Fv	fragments	by	two-membered	culture	of	the	separate	VL-	and	 VH-expression	 strains	 in	 Brevibacillus	 chosinensis	 secretory	 system14	 is	problematic	when	either	strain	proliferates	too	rapidly.	
To	solve	these	problems,	we	have	developed	a	new	expression	strategy	in	which	 the	stoichiometric	 secretion	and	assembly	of	 the	VL	and	VH	domains	are	achieved	 by	 monocistronic	 expression	 in	 the	 Gram-positive	 bacterium	 B.	
choshinensis.	 A	 polyhistidine-maltose	 binding	 protein	 (His6-MBP)	 cassette,	embedded	within	the	intervening	region	of	the	two	variable	domains,	serves	as	an	 affinity	 purification	 tag	 that	 can	 be	 removed	 by	 tobacco	 etch	 virus	 (TEV)	protease	cleavage.	We	chose	the	name	“iRAT	(intervening	removable	affinity	tag)	system”	 to	 describe	 this	 production	 strategy.	 Here,	 we	 present	 a	 reliable	 and	
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We	 developed	 the	 iRAT	 system	 to	 address	 the	 need	 for	 a	 reliable	 method	 to	control	the	1:1	stoichiometric	expression	and	the	proper	folding	of	the	VL	and	VH	domains,	 each	 of	which	 contains	 an	 intrachain	 disulfide	 bond.	 To	 increase	 the	throughput	of	crystallization	trials,	it	is	ideal	to	collect	soluble	and	functional	Fv	fragments	with	 high	 yields	 by	 using	 simple	 purification	 procedures	without	 in	
vitro	 refolding,	 a	 time	 and	 labor	 intensive	 process.	 Considering	 these	prerequisites,	we	generated	a	synthetic	polyprotein	encoding	both	the	VL	and	VH	domains	 by	 using	 a	 monocistronic	 expression	 strategy	 in	 a	 Gram-positive	bacterial	 secretion	 system.	 Specifically,	 the	 new	 expression	 vector	 pBIM2	contained	the	VL-	and	VH-coding	sequences	cloned	in	a	single	reading	frame	(Fig.	1A).	 The	 two	 variable	 domains	 were	 tethered	 together	 by	 the	 iRAT	 segment,	which	contained	the	first	TEV	cleavage	site,	the	His6	tag,	a	 linker,	MBP,	another	linker	and	the	second	TEV	cleavage	site	 in	that	order.	The	 iRAT	portion	can	be	removed	 by	 cleavage	 with	 His6-tagged	 TEV	 protease	 (TEV-His6)	 followed	 by	
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reverse	 immobilized	 metal-affinity	 chromatography	 (IMAC)	 (Fig.	 1B	 and	Methods).	 MBP	 was	 included	 to	 enhance	 the	 secretory	 expression	 of	 the	synthetic	polyprotein.	The	purification	yields	for	iRAT-based	Fv	expression	were	1.5	 to	 1.7-fold	 higher	 than	 those	 of	 the	 non-MBP	 fusion.	 Another	 reason	 for	including	MBP	is	that	the	distance	between	the	N-	and	C-termini	(43	Å)	is	similar	to	 the	 distance	 between	 the	 C-terminus	 of	 VL	 and	 the	 N-terminus	 of	 VH	(approximately	 35-40	 Å)	 for	 most	 Fv	 fragments20.	 The	 construct	 was	 cloned	downstream	of	the	constitutively	active	promoter	P5	and	the	Sec	signal	peptide	for	polyprotein	secretion	into	the	culture	supernatant.	
	
iRAT-based	 production	 of	 a	 crystallization	 chaperone	 for	 the	 rat	 fructose	
transporter	GLUT5		
In	a	previous	study,	an	Fv	fragment	(clone	number:	4D111)	was	used	to	improve	the	crystallization	of	the	rat	GLUT5	fructose	transporter14.	We	tested	the	large-scale	 expression	 and	 purification	 of	 the	 Fv	 4D111	 by	 using	 the	 iRAT	 system.	
Brevibacillus	cells	harboring	the	pBIM2-based	construct	were	cultivated	for	48	h.	Afterward,	 Fv	 4D111	 was	 purified	 from	 the	 culture	 supernatant	 by	 using	ammonium	sulfate	precipitation	followed	by	IMAC,	TEV	cleavage,	reverse	IMAC	and	 size	 exclusion	 chromatography	 (SEC)	 (Methods).	 The	 yield	 of	 purified	 Fv	4D111	was	 4.1	mg	 per	 liter	 of	 culture,	 and	 no	 apparent	 aggregation	 occurred	when	the	purified	protein	was	concentrated	to	~10	mg/mL.	A	typical	SEC	elution	profile	for	Fv	4D111	is	shown	in	Figure	2A.	The	elution	peak	was	monodisperse,	and	oligomer	formation	was	not	observed.	Calibration	with	molecular	standards	revealed	that	the	Fv	4D111	existed	as	a	monomer	in	solution	with	an	apparent	
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molecular	weight	 of	 ~26	 kDa.	 SDS-PAGE	 under	 reducing	 conditions	 showed	 a	double	band	with	the	expected	mobility	of	the	VL	and	VH	domains	(Fig.	2B).	
	 To	 test	whether	 the	purified	Fv	 fragment	was	 functional,	 SEC	of	 the	 rat	GLUT5	transporter	in	complex	with	Fv	4D111	was	performed.	A	molar	excess	of	Fv	 4D111	 was	 mixed	 with	 GLUT5	 and	 loaded	 onto	 an	 SEC	 column.	 Complex	formation	 was	 indicated	 by	 an	 elution	 peak	 shift	 toward	 higher	 molecular	weights,	as	compared	with	uncomplexed	GLUT5	(Fig.	2C).	SDS-PAGE	analysis	of	the	high	molecular	weight	peak	clearly	showed	the	presence	of	both	GLUT5	and	Fv	4D111	(Fig.	2D).	Surface	plasmon	resonance	(SPR)	experiments	indicated	that	iRAT-produced	Fv	4D111	bound	GLUT5	with	a	KD	value	of	2.4	nM	(Fig.	2E).	The	thermal	stability	of	GLUT5	in	the	presence	or	absence	of	Fv	4D111	indicated	that	this	 antibody	 fragment	 increased	 the	Tm	by	 12.5°C	 after	 GLUT5	 binding,	 thus	suggesting	 that	 Fv	 4D111-bound	 GLUT5	 was	 significantly	 stabilized	 (Fig.	 2F).	Furthermore,	the	GLUT5-Fv	4D111	complex	was	able	to	be	crystallized	(Fig.	2G,	inset).	The	co-crystals	diffracted	up	to	3.2	Å	and	generated	complete	diffraction	sets,	 which	were	 able	 to	 be	 processed	 to	 solve	 the	 structure	 of	 the	 GLUT5-Fv	complex	 (Fig.	 2G).	These	 results	 suggest	 that	 the	 iRAT	 system	 is	useful	 for	 the	production	 of	 Fv	 scaffold-based	 crystallization	 chaperones	 in	 milligram	quantities.	
	
iRAT-based	 production	 of	 Fv	 fragments	 of	 therapeutic	 antibodies	 for	 co-
crystallization	with	their	targets	
A	 structure-based	 understanding	 of	 the	 interactions	 between	 therapeutic	
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antibodies	 and	 target	 proteins	 is	 critical	 to	 the	 rational	 design	 of	 improved	biotherapeutics.	However,	 a	 relatively	 small	 number	 of	 crystal	 structures	 have	been	 determined	 for	 therapeutic	 antibody-target	 protein	 complexes,	 which	probably	 reflects	 the	 lack	 of	 simple	 methods	 facilitating	 production	 of	recombinant	 antibody	 fragments	 in	 milligram	 quantities,	 resulting	 in	 limited	success	 in	 co-crystallization	 trials.	 Typical	 examples	 include	 certolizumab	 and	denosumab.	Certolizumab	is	a	humanized	monoclonal	antibody	that	targets	the	tumor	 necrosis	 factor	α	 (TNFα)	 and	 is	 used	 to	 treat	 rheumatoid	 arthritis	 and	Crohn’s	disease21.	Denosumab	is	a	human	monoclonal	antibody	that	targets	the	receptor	 activator	 of	 nuclear	 factor	 κB	 ligand	 (RANKL)	 and	 is	 used	 to	 treat	osteoporosis,	 treatment-induced	 bone	 loss,	 metastases	 to	 bone,	 and	 giant	 cell	tumors	of	the	bone22.	Although	the	U.S.	FDA	has	approved	these	two	antibodies,	the	interactions	between	the	antibodies	and	their	target	molecules	have	not	been	accurately	 mapped	 at	 atomic-level	 resolution	 by	 crystallographic	 analyses.	 To	demonstrate	 the	utility	of	 the	 iRAT	system,	we	produced	Fv	 fragments	derived	from	these	two	therapeutic	antibodies.	
	 Amino	 acid	 sequence	 data	 for	 the	 antibodies	 were	 retrieved	 from	DrugBank	(http://www.drugbank.ca/).	Codon-optimized	cDNAs	encoding	the	VL	and	VH	domains	were	artificially	synthesized	and	cloned	into	the	pBIM2	vector.	The	certolizumab	Fv	and	the	denosumab	Fv	were	readily	expressed	and	purified	to	 greater	 than	95%	purity	with	 yields	 of	 15.4	 and	1.0	mg	per	 liter	 of	 culture,	respectively.	 Excess	 amounts	 of	 each	 of	 the	 purified	 Fv	 fragments	were	mixed	with	the	corresponding	target	protein.	The	resulting	complexes	appeared	to	be	monodisperse,	 as	 indicated	 by	 the	 SEC	 analysis	 (Figs.	 3A	 and	 3D).	 SDS-PAGE	
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analysis	 confirmed	 that	 the	 higher-molecular-weight	 peak	 fractions	 contained	the	Fv	fragment	and	its	target	cytokine,	thus	indicating	tight	complex	formation	between	them	(Figs.	3B	and	3E).	Purified,	concentrated	complexes	were	used	to	set	up	broad	crystallization	screens,	and	the	crystallization	conditions	were	then	optimized	 by	 varying	 the	 precipitant	 concentration.	 Promising	 crystals	 whose	complete	 diffraction	 data	 sets	were	 collected	 are	 shown	 in	 Figures	 3C	 and	 3F.	The	data	collection	statistics	are	shown	 in	Table	1.	Molecular	replacement	was	performed	using	the	Fv	4D111	structure	(PDB	ID:	4YBQ,	chains	C	and	D)	as	the	search	model,	and	 interpretable	electron-density	maps	were	obtained.	Electron	densities	 corresponding	 to	 either	 TNFα	 or	 RANKL	 were	 observed,	 and	model	building	and	structure	refinement	are	under	way.	
	
Discussion	
Fab	fragments	are	the	most	commonly	used	crystallization	chaperones.	However,	they	are	relatively	large	co-crystallization	partners	of	approximately	500	amino	acids,	and	they	often	generate	crystal	lattices	with	one	or	more	large	cell	edges,	which	 can	 cause	 diffraction	 spots	 to	 overlap	 and	 complicate	 structural	determination.	 The	 flexibility	 of	 the	 elbow	 angle	 between	 the	 variable	 and	constant	 domains	 in	 Fab	 fragments	 sometimes	 hinders	 crystallization.	 Fv	fragments	 can	 be	 used	 as	 complementary	 and	 alternative	 crystallization	chaperones	with	having	all	the	features	of	the	binding	interface	present	in	larger	Fab	fragments.	Single-chain	Fv	(scFv)	fragments	are	similar	to	Fv	fragments,	but	the	 linker	 between	 the	 VL	 and	 VH	 domains	 makes	 scFv	 fragments	 prone	 to	forming	 intermolecularly	 domain-swapped	 dimers23.	 The	 dimer-monomer	
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equilibrium	of	 scFv	 fragments	 can	 increase	 structural	heterogeneity;	 therefore,	an	 antibody	 in	 scFv	 format	 is	 less	 desirable	 for	 crystallization.	 In	 addition,	 Fv	fragments	are	less	prone	to	distortion	than	scFv	fragments	because	aggregation	of	 scFv	 fragments	 is	 sensitive	 to	 the	 linker	 length.	 Nanobodies	 (VHHs)	 are	increasingly	finding	favor	with	crystallographers	due	to	their	small	size,	ease	of	expression	and	purification,	and	extreme	structural	stability.	Another	fascinating	feature	of	Nanobodies	is	their	extended	convex	paratope	structure	that	can	bind	deep	into	molecular	clefts	to	trap	the	target	in	a	particular	conformational	state4.	However,	 Fv	 fragments	 have	 an	 advantage	 over	 Nanobodies	 in	 more	 efficient	enlargement	 of	 hydrophilic	 surfaces	 for	 crystal	 contacts	 because	 of	 the	 larger	molecular	size.	
Fv	fragments	are	heterodimeric	molecules	consisting	of	two	domains,	VL	and	VH,	 that	assemble	 through	hydrophobic	 interactions.	Each	of	 the	VL	and	VH	domains	contains	an	intrachain	disulfide	bond	for	stabilization.	These	structural	properties	require	a	sophisticated	apparatus	for	secretion,	folding,	and	assembly	as	well	as	an	oxidizing	environment	for	disulfide	bond	generation.	B.	choshinensis	is	well	known	for	 its	capacity	to	secrete	 large	amounts	of	proteins	directly	 into	the	 culture	 medium.	 Expression	 of	 Fv	 fragments	 via	 the	 B.	 choshinensis	 Sec-dependent	 secretion	pathway	ensures	 the	 formation	of	 the	 intrachain	disulfide	bonds	 to	 stabilize	 the	 structure.	 Thus,	 we	 combined	 the	 advantages	 of	monocistronic	 stoichiometric	 expression	with	 those	 of	 Gram-positive	 bacterial	secretory	expression	to	develop	the	iRAT	system.	To	make	this	system	suitable	for	structural	studies,	the	linker	segment	that	tethers	the	VL	and	VH	domains	can	be	 cleaved	 by	 the	 site-specific	 protease	 and	 removed	 during	 the	 purification	
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process.		
The	 iRAT	 system	 is	 a	 streamlined	 pipeline	 that	 provides	 the	 desired	intermediate	throughput	to	produce	many	Fv	 fragments	 in	parallel.	The	typical	duration	for	running	one	cycle	of	the	iRAT-production	procedure,	from	plasmid	construction	to	protein	purification,	is	10	days.	The	procedure	is	easy	and	cost-effective	and	does	not	require	any	time-consuming	or	labor-intensive	steps.	The	iRAT	 system	generally	 produces	high	Fv	 fragment	purification	 yields	 sufficient	for	 structural	 studies.	 We	 have	 tested	 the	 iRAT-based	 expression	 and	purification	 of	 randomly	 chosen	 17	 different	 Fv	 fragments	 and	 found	 that	 the	yields	exceed	3	mg	per	liter	of	culture	in	12	out	of	them	(data	not	shown).	These	yields	considerably	exceed	those	obtained	from	equivalent	constructs	expressed	in	 the	E.	coli	 periplasm.	A	 limitation	of	 the	 iRAT	 system	 is	 the	 yield	 variability	among	individual	antibody	clones,	which	can	be	attributed	to	the	sequence	of	the	variable	domains	and	the	stability	of	the	hydrophobic	interactions	between	them.	However,	we	have	not	identified	specific	sequence	motifs	and	other	factors	that	affect	the	yields;	hence	the	yield	cannot	be	judged	in	advance	on	the	basis	of	the	sequence	information	alone.	





The	pBIM2	vector	(Fig.	1A)	for	expression	of	Fv	fragments	was	designed	on	the	basis	 of	 the	 backbone	 of	 the	Brevibacillus	 plasmid	 pNY326	 (Clontech).	 The	VL-insertion	site,	iRAT	cassette	and	VH-insertion	site	were	tandemly	arranged	in	this	order	and	introduced	downstream	of	the	constitutively	active	P5	promoter	and	the	Sec	secretion	signal	sequence.	The	iRAT	cassette	encoded	the	N-terminal	TEV	cleavage	site,	His6	tag,	a	9-residue	Gly/Ser-rich	linker,	the	MBP	coding	sequence	(residues	 27	 to	 392	 from	UniProt	 ID:	 P0AEX9),	 a	 25-residue	 Asn/Gly/Ser-rich	linker	and	a	C-terminal	TEV	cleavage	site	(Supplementary	Fig.	1).	Residues	1-107	(Kabat	numbering	scheme)	of	the	VL	domain	and	1-113	of	the	VH	domain	derived	from	 monoclonal	 antibodies	 were	 used	 for	 Fv	 fragment	 expression.	 The	artificially	synthesized,	codon-optimized	cDNAs	encoding	the	VL	and	VH	domains	were	amplified	with	primers	that	included	5’	overhangs	(27	bp)	complementing	the	 upstream	 and	 downstream	 sequences	 to	 the	 pBIM2	 vector	 junctions.	 The	iRAT	 segment	 was	 amplified	 with	 the	 two	 primers	 BIM2-F	 (5’-	ACTAGTGAAAATTTATATTTTCAAGGTCACCATCACCATCACCATTCCTCTGGTGGCGGT)	 and	 BIM2-R	 (5’-	AAGCTTCGATTGGAAGTACAGGTTTTCGGAAGATCTAGAGGAACCACCCCCACCCCCGAG).	The	pNY326	backbone	was	amplified	with	the	two	primers	pNY326-F	(5’-	GAATTCGGTACCCCGGGTTCGA)	 and	 pNY326-R	 (5’-	GGATCCTGCAGCGAAAGCCATGGGAGC).	 A	 total	 of	 four	 PCR-amplified	 DNA	fragments	 for	each	antibody	clone	were	added	 to	Gibson	Assembly	Master	Mix	(New	England	Biolabs)	and	incubated	at	50°C	for	60	min.	B.	choshinensis	HPD31-
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SP3	 cells	 (Clontech)	 were	 electroporated	 with	 the	 assembled	 DNA	 under	conditions	of	7.5	kV/cm,	25	μF,	and	1000	Ω.	The	transformants	were	selected	on	plates	 supplemented	 with	 50	 mg/L	 neomycin.	 The	 resulting	 plasmids	 were	extracted	with	a	conventional	miniprep	kit.	For	SPR	experiments,	a	derivative	of	Fv	4D111	with	an	HA	tag	at	 the	C-terminus	of	 the	VH	domain	was	constructed.	Preparation	of	the	pBIM2-based	plasmid	typically	took	3	days.	
	 Construction	of	the	expression	plasmid	for	Homo	sapiens	TNFα	was	also	on	 the	 basis	 of	 the	 pNY326	 plasmid	 backbone.	 The	 extracellular	 domain	 of	human	TNFα	(UniProt	ID:	P01375,	residues	77	to	233)	was	FLAG-tagged	at	the	N-terminus.	To	facilitate	detection	and	purification,	a	TEV	cleavage	site	and	His6-HA	tag	were	added	at	the	C-terminus.	The	construct	was	inserted	downstream	of	the	P5	promoter	and	Sec	secretion	signal	sequence.	
Construction	of	 the	expression	plasmid	 for	H.	sapiens	RANKL	was	based	on	the	backbone	of	the	E.	coli	plasmid	pBAD-Myc	His	(Thermo	Fisher	Scientific).	The	extracellular	domain	of	human	RANKL	(UniProt	ID:	O14788,	residues	162	to	317)	was	fused	with	NusA,	a	His6	tag,	a	23-residue	linker	and	a	TEV	cleavage	site	at	the	N-terminus.	The	construct	was	inserted	downstream	of	the	PBAD	promoter.	




The	 Fv	 fragments	 and	 human	 TNFα	 were	 expressed	 in	 B.	 choshinensis	 and	secreted	into	the	culture	medium.	B.	choshinensis	cells	harboring	the	expression	plasmids	were	grown	overnight	at	30°C	and	200	rpm	 in	2SY	medium	(soytone	40	g/L,	 yeast	 extract	5	g/L,	 glucose	20	g/L,	 and	CaCl2	0.15	g/L)	 supplemented	with	50	mg/L	neomycin.	The	culture	was	diluted	1:100	into	1	L	of	2SY	medium	in	 2.5	 L	 baffled	 Tunair	 shaker	 flasks	 and	 grown	 for	 48-60	 h.	 The	 cells	 were	removed	by	 centrifugation	at	6,000	g	 for	15	min.	The	 culture	 supernatant	was	adjusted	 to	 a	 final	 ammonium	 sulfate	 concentration	 of	 60%	 saturation.	 The	precipitate	was	pelleted,	dissolved	 in	TBS	buffer	 (10	mM	Tris-HCl,	pH	7.5,	150	mM	NaCl),	and	dialyzed	overnight	against	the	same	buffer.	The	dialyzed	sample	was	mixed	with	Ni-NTA	resin	(Qiagen)	equilibrated	with	buffer	A	(10	mM	Tris-HCl,	pH	7.5,	150	mM	NaCl,	and	20	mM	imidazole).	Bound	proteins	were	eluted	with	buffer	B	(10	mM	Tris-HCl,	pH	7.5,	150	mM	NaCl,	and	250	mM	imidazole),	mixed	 with	 TEV-His6	 and	 dialyzed	 overnight	 against	 TBS	 buffer.	 The	 cleaved	His6-tagged	 portion	 (the	 iRAT	 segment	 of	 the	 Fv-containing	 polyprotein	 or	 C-terminal	His6-HA	tag	of	the	TNFα)	and	TEV-His6	were	removed	using	a	HisTrap	HP	 column	 (GE	 Healthcare)	 equilibrated	 with	 buffer	 A.	 The	 flow-through	fractions	 were	 concentrated	 and	 loaded	 onto	 a	 HiLoad16/60	 Superdex75	column	 (GE	Healthcare)	 equilibrated	with	TBS	buffer.	The	peak	 fractions	were	pooled,	 concentrated,	 flash	 frozen	 in	 liquid	 nitrogen,	 and	 stored	 at	 -80°C.	 The	typical	duration	for	this	procedure	was	7	days.	
E.	coli	 TOP10	 cells	 harboring	 the	 expression	plasmid	 for	human	RANKL	were	grown	overnight	at	37°C	and	250	rpm	in	LB	supplemented	with	100	mg/L	ampicillin.	The	culture	was	diluted	1:100	into	200	mL	of	the	same	medium	and	
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grown	at	37°C	to	an	OD600	of	0.5	followed	by	overnight	incubation	at	20°C	with	0.02%	arabinose.	The	 cells	were	harvested	by	 centrifugation	 at	 6,000	g	 for	 15	min	and	re-suspended	 in	buffer	S1	 (10	mM	Tris-HCl,	pH	8.0,	150	mM	NaCl,	20	mM	 imidazole,	 0.1%	Triton	X-100,	Roche	EDTA-free	 protease	 inhibitor	 tablet).	Cells	were	disrupted	by	sonication	 followed	by	DNaseI	 treatment	on	 ice	 for	30	min.	The	lysate	was	clarified	via	centrifugation	and	loaded	onto	a	HisTrap	Crude	column	(GE	Healthcare)	equilibrated	with	buffer	A.	Bound	proteins	were	eluted	with	buffer	B,	mixed	with	TEV-His6	 and	dialyzed	overnight	 against	TBS	buffer.	The	 cleaved	 NusA-His6	 tag	 and	 TEV-His6	 were	 removed	 using	 a	 HisTrap	 HP	column	 equilibrated	 with	 buffer	 A.	 The	 flow-through	 fractions	 were	concentrated	and	loaded	onto	a	Superdex200	10/300GL	column	(GE	Healthcare)	equilibrated	with	TBS	buffer.	The	peak	fractions	were	pooled,	concentrated,	flash	frozen	in	liquid	nitrogen,	and	stored	at	-80°C.	
	 Rat	 GLUT5	 was	 expressed	 and	 purified	 using	 previously	 described	methods14.	
	
SPR	experiments	
SPR	 experiments	 were	 performed	 at	 20°C	 using	 a	 Biacore	 T100	with	 series	 S	streptavidin	 sensor	 chips	 (Series	 S	 sensor	 chip	 SA;	 GE	 Healthcare)	 in	 TBS	containing	0.05%	dodecyl-β-D-maltopyranoside	(DDM).	Biotinylated	anti-HA	IgG	(Rockland	 Immunochemicals)	 was	 captured	 on	 the	 streptavidin	 surface	 (flow	cells	1	 and	2)	with	 a	400	 sec	 injection	of	50	μg/mL	of	 antibody	at	10	μL/min.	Purified	samples	of	the	HA-tagged	Fv	4D111	with	12	mg/mL	BSA	and	12	mg/mL	
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CM-dextran	were	 subsequently	 injected	 (500	 μL	 at	 a	 flow	 rate	 of	 10	 μL/min)	over	 flow	 cell	 2.	 GLUT5	 at	 various	 concentrations	 was	 simultaneously	 passed	over	flow	cells	1	and	2	at	a	flow	rate	of	30	μL/min.	Association	and	dissociation	times	 were	 2	 and	 5	 min,	 respectively.	 Regeneration	 consisted	 of	 a	 30	 sec	injection	 of	 10	 mM	 NaOH.	 Flow	 cell	 1	 was	 used	 as	 a	 reference	 surface.	 Data	analysis	was	performed	using	BIAevaluation	software	(GE	Healthcare).	
	
Thermal	stability	assay	
The	thermal	stability	of	GLUT5	was	evaluated	 in	the	presence	or	absence	of	Fv	4D111	 using	 the	 thiol-specific	 fluorochrome	 N-[4-(7-diethylamino-4-methyl-3-coumarinyl)phenyl]maleimide	 (CPM),	 as	 described	 previously24	 with	 minor	modifications.	Briefly,	19.5	µL	GLUT5	or	GLUT5-Fv	4D111	complex	(0.2	nmol)	in	TBS	 containing	 0.02%	DDM	was	mixed	with	 0.5	 µL	 CPM	 dye	 (4	mg/mL).	 The	reaction	mixture	was	 transferred	 to	 a	 clean	PCR	 tube	 and	heated	with	 a	 ramp	rate	of	3°C/min	in	a	My	iQ2	thermal	cycler	(Bio-Rad).	The	excitation	wavelength	was	set	to	365	nm	and	the	emission	wavelength	was	set	to	460	nm.	Assays	were	performed	over	a	temperature	range	of	4°C	to	80°C.	Melting	temperatures	(Tm)	were	determined	by	fitting	the	curves	to	a	sigmoidal	dose-response	equation.	
	
Crystallization	
The	protein	complex	was	prepared	by	incubating	the	target	protein	with	the	Fv	fragment	 at	 a	molar	 ratio	of	1:2	 for	1	h	on	 ice.	 Size	 exclusion	 chromatography	was	performed	on	the	complex	(Superdex	200	10/300	column,	GE	Healthcare),	
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which	was	equilibrated	with	TBS	containing	0.02%	DDM	(GLUT5-Fv	4D111)	or	TBS	 (TNFα-certolizumab	 Fv	 and	 RANKL-denosumab	 Fv).	 Peak	 fractions	containing	 the	 complexes	 were	 concentrated	 to	 approximately	 10	 mg/mL	 by	ultrafiltration	 (Millipore,	 MWCO	 10	 kDa)	 and	 used	 for	 the	 crystallization	experiments.		
The	 crystals	 used	 for	 the	 X-ray	 diffraction	 experiments	were	 grown	 for	14-20	 days	 at	 20°C	 by	 hanging	 drop	 vapor	 diffusion.	 A	 400	 µL	 reservoir	 was	equilibrated	 against	 a	 2	µL	 drop	 containing	 a	 1:1	mixture	 of	 the	 complex	 and	reservoir	 solution.	 For	 GLUT5-Fv	 4D111	 co-crystallization,	 the	 reservoir	contained	0.1	M	Tris-HCl	(pH	8.0),	0.12	M	CaCl2	and	33-35%	PEG400.	For	TNFα-certolizumab	 Fv	 co-crystallization,	 the	 reservoir	 contained	 0.1	 M	 tri-sodium	citrate/citric	 acid	 (pH	 5.6)	 and	 50%	 PEG3000.	 For	 RANKL-denosumab	 Fv	 co-crystallization,	the	reservoir	contained	0.1	M	sodium	acetate/acetic	acid	(pH	4.6)	and	 2	 M	 NaCl.	 The	 GLUT5-Fv	 4D111	 co-crystals	 were	 flash-frozen	 in	 liquid	nitrogen.	 The	 co-crystals	 of	 TNFα-certolizumab	 Fv	 and	 RANKL-denosumab	 Fv	were	cryo-protected	in	25%	ethylene	glycol	in	the	mother	liquor	and	then	flash-frozen	in	liquid	nitrogen.	
	
Diffraction	data	collection	and	analysis	
The	diffraction	data	were	 collected	 at	100	K	at	 the	 SPring-8	beamline	BL41XU	(Japan)	 using	 a	 MX225HE	 (Rayonix)	 or	 PILATUS3	 6M	 (Dectris)	 detector.	 The	data	 were	 then	 integrated	 and	 scaled	 using	 HKL200025	 or	 XDS26.	 Molecular	replacement	 was	 performed	 with	 the	 MR-PHASER	 program27.	 The	 atomic	
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coordinates	of	Fv	4D111	 (PDB	 ID:	4YBQ,	 chains	C	and	D)	 served	as	 the	 search	models.	The	model	was	further	rebuilt	in	COOT28.		
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Table	1.		Data	collection	statistics		 TNFα-certolizumab	Fv	complex	 RANKL-denosumab	Fv	complex	X-ray	source	 BL41XU,	SPring-8	 BL41XU,	SPring-8	Wavelength	(Å)	 1.0	 1.0	Space	group	 C2	 I4132	Cell	dimension	 	 			a,	b,	c	(Å)	 101.4,	110.45,	133.6	 192.5,	192.5,	192.5	
  α,	β, γ (°) 90.0,	105.3,	90.0	 90.0,	90.0,	90.0	Total	No.	of	reflection				measured	 496486	(21314)	 1128891	(80799)	No.	of	unique				reflections	 82561	(6027)	 29117	(2123)	Resolution	range	(Å)	 50-2.10	(2.15-2.10)		 48.15-2.25	(2.31-2.25)		




Figure	1.	 	 	Expression	construct	for	production	of	Fv	fragments	via	iRAT	system.	(A)	Schematic	diagram	 and	 construction	 strategy	 of	 the	 pBIM2	 plasmid.	 The	 VL-	 and	 VH-encoding	 cDNAs	 are	amplified	with	PCR	primers	containing	27-nucleotides	5’	overhangs,	which	act	as	 ‘guiding	ends’	in	the	subsequent	Gibson	assembly	reaction.	(B)	iRAT-systhetic	polyproteins	are	used	to	produce	Fv	 fragments	 in	 high	 quality	 and	 quantity	with	Brevibacillus	 secretory	 expression	 system.	 The	resulting	polyproteins	are	recovered	form	the	culture	supernanant,	purified	by	IMAC	and	excised	with	TEV-His6	(indicated	by	 ‘scissors’	 icon).	After	removal	of	the	 iRAT	portion	and	TEV-His6	by	reverse	IMAC,	non-tagged	Fv	fragments	are	further	purified	by	SEC.	VL	is	colored	in	red,	iRAT	in	green	and	VH	in	blue.	VL	N-terminus,	VH	C-terminus	and	CDR	surface	are	marked.		
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Supplementary	 Figure	 1.	 Structure	 of	 the	 iRAT-based	 Fv	 expression	 vector	 pBIM2.	 (A)	Schematic	 illustration	 of	 the	 region	 containing	 the	 promoter,	 secretion	 signal	 and	 iRAT-polyprotein	construct.	(B)	Sequence	corresponding	to	the	region	shown	in	(A).	P5-35	and	P5-10	represent	the	-35	and	-10	box	of	the	promoter	P5,	respectively.	SD1	and	SD2	are	Shine-Dalgarno	sequences.	The	Sec	secretion	signal,	TEV	recognition	sequence,	His6	 tag	and	MBP	are	shown	 in	gray,	 orange,	 yellow	and	green,	 respectively.	Gray	arrowheads	 indicate	 the	 signal	 cleavage	 site	and	TEV	cleavage	sites.	
